News

15 Dec 2017

Incentives for Innovation. Incentivising Research in Areas of High Unmet Medical Need: Lilly’s Alzheimer’s Quest

With over 7,000 medicines in development, new treatments will continue to change patients’ lives, slowing disease progression, avoiding illness and reducing overall costs for healthcare systems....

Read more
12 Dec 2017

Presentations from the 6th EBE Annual Conference on ATMPs – 5 December 2017, London

The remarkable opportunities that cell and gene therapies can offer, but also the seemingly increasing number of obstacles to their wide application, were presented to a full audience in London’...

Read more
08 Dec 2017

Incentives, IP and smaller companies: the story of Lysogene

How Lysogene contributes to improving health outcomes Founded in France in 2009, and employing 18 staff at the end of 2017, Lysogene specialises in gene therapy targeting rare, neurod...

Read more
05 Dec 2017

Escher Study Identifies Hurdles to ATMP Development in Europe

First results of a study into factors associated with successful development of Advanced Therapy Medicinal Products (ATMPs) were reported today by Utrecht University at European Biopharmaceuti...

Read more
01 Dec 2017

Incentives for Innovation: the story of Gilenya by Novartis

With over 7,000 medicines in development, new treatments will continue to change patients’ lives, slowing disease progression, avoiding illness and reducing overall costs for healthcar...

Read more
30 Nov 2017

EBE Concept Paper: Management and Control of Raw Materials Used in the Manufacture of Biological Medicinal Products

Effective management and control of raw materials (RM) used in the manufacture of biological medicinal products requires an appropriate framework to identify and focus on critical aspects that must be...

Read more
24 Nov 2017

Incentives, IP and smaller companies – the story of Transgene

How Transgene wants to change patients’ lives by improving health outcomes Transgene S.A., founded in December 1979, and part of the French Institut Mérieux since 1994, focuses on designing...

Read more
17 Nov 2017

Incentives, IP and smaller companies – the story of Vaxeal

Vaxeal Holding SA is headquartered in Vevey, Switzerland, with operations in Evry and Paris, France. The company was created in 2009. It develops therapeutic vaccines in combination with immune ch...

Read more
10 Nov 2017

Incentives, IP and smaller companies – the story of Chiesi and Holostem

Chiesi and Holostem Terapie Avanzate have jointly developed Holoclar, the first stem-cell-based product to be approved in Europe. Chiesi licenses the international marketing authorization for Holo...

Read more
02 Nov 2017

Incentives, IP and smaller companies – the story of TiGenix

How TiGenix wants to change patients’ lives by improving health outcomes TiGenix NV (Euronext Brussels and NASDAQ: TIG) is an advanced Belgian biopharmaceutical SME with operations in Madrid, S...

Read more
1 2 3 6